Improved PFS and OS Correlated With Undetectable METex14 Following Savolitinib in NSCLC
April 11, 2021

Patients with non‒small cell lung cancer with undetectable circulating tumor MET Exon 14 following treatment with savolitinib are more likely to have positive progression-free and overall survival outcomes.

Parsaclisib Plus Ruxolitinib to Treat Myelofibrosis Improves Spleen Size and Symptom Burden
April 11, 2021

Adding parsaclisib to the ruxolitinib treatment of patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone led to improvements in spleen volume reduction and symptom burden.

Limited Efficacy, Manageable Safety Profile Found With TAS-117 to Treat Ovarian and Breast Cancer
April 11, 2021

TAS-117 showed limited clinical efficacy in treating patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.